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Objective: To assess the efficacy of 2% clindamycin vaginal cream (CVC) to treat bacterial vaginosis (BV) in
pregnancy.
Methods: A prospective, randomized, double-blind, placebo-controlled, tricenter study. Four hundred and four
women with BV on Gram stain at their first antenatal clinic visit were randomized to receive a 3-day course of
2% CVC or placebo. The outcome was assessed using an intention to treat analysis at 3 weeks and 6 weeks
post-treatment according to three different diagnostic methods based on five criteria (Gram stain and all four
elements of clinical composite criteria: vaginal discharge, abnormal vaginal pH, clue cells, amine odor), three
criteria (vaginal pH, clue cells, amine odor) or two criteria (clue cells and amine odor) to reflect stringency of
diagnosis, historical precedence and government agency recommendations respectively.
Results: Using five diagnostic criteria, 18% of CVC patients were cured and 70.8% either cured and/or improved
compared to 1.6% and 12% of placebo patients respectively (p < 0.0001). Using three diagnostic criteria, 44.8%
of CVC patients were cured and 77.3% were either cured and/or improved compared to 9.3% and 28.8% of
placebo patients respectively (p < 0.0001). Using two diagnostic criteria, 75.0% of CVC patients were cured
compared to 18.0% of placebo patients (p < 0.0001). Recurrence rates in those CVC patients successfully treated
were approximately 6% at 6 weeks post baseline and 10% at 28 to 34 weeks gestation.
Conclusions: A 3-day course of CVC appears to be well tolerated by the mother and statistically significantly
more efficacious than placebo in the treatment of BV during the second trimester of pregnancy.
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Bacterial vaginosis (BV) is a common poly-
microbial condition previously known by a variety
of names. It is associated with a reduction in the
number and quality of lactobacilli, together with a
1000-fold increase in other organisms, such as
anaerobes, Mycoplasma hominis and Gardnerella
vaginalis. These changes in the vaginal flora are
reflected in the appearance of a Gram stain of
vaginal secretions and form the basis of diagnosis1,2.
The disease is detected clinically by the observa-
tion of a set of signs first described by Amsel and
co-workers in 1983 and adopted as the common
clinical criteria for diagnosis and assessment of
treatment3. A number of studies have shown that
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BV is associated with a two- to five-fold increased
risk of preterm birth which is the greatest cause of
perinatal mortality and morbidity in the developed
world. The earlier in pregnancy at which BV is
diagnosed, the greater is the relative risk of adverse
outcome4. For this reason and also because BV can
cause a malodorous vaginal discharge, it may be
necessary to treat BV in pregnancy. The Centers
for Disease Control and Prevention (Atlanta, GA,
USA) have recommended that all women who
have symptomatic disease require treatment
regardless of pregnancy status and that there is
enough evidence of benefit from prophylaxis to
reduce the incidence of preterm birth that
high-risk pregnant women who do not have
symptoms of BV may be evaluated for treatment5.
To prevent adverse fetomaternal side-effects, it
would be more appropriate to use local rather than
systemic therapy. This study is unique in that it is
the only study to have evaluated the efficacy
and safety of a 3-day course of 2% intravaginal
clindamycin cream for the treatment of BV in
pregnancy.
SUBJECTS AND METHODS
The study was a prospective, randomized block,
double-blind, placebo-controlled, parallel study
group carried out over a 3-year period. Inclusion
criteria required women to be pregnant, asymp-
tomatic, aged 16 to 40 years, with a live fetus
between 13 and 20 weeks gestation at their first
antenatal clinic visit and with a Gram stain of
vaginal secretions consistent with a diagnosis of
BV1. Women were excluded if they had a known
sensitivity to clindamycin, a history of anti-
biotic-related colitis, inflammatory bowel disease
or frequent periodic diarrhea or if they had a
concomitant sexually transmitted disease (STD).
During application of the cream, women were
encouraged to abstain from sexual intercourse.
Women were to self administer 5 g of intravaginal
clindamycin cream (CVC) equivalent to 100 mg
of clindamycin or placebo, at night for three con-
secutive nights before retiring to bed. If women
had sexual intercourse they were advised to use a
condom during the time of treatment. Treatments
were assigned using a computerized, randomized
block procedure with a block size of 10 using
a computer-generated random code list. The
investigational drug and the placebo cream were of
identical composition except for the active drug
which accounted for a small proportion of the
overall formulation. Active and placebo creams
were packaged identically and labeled only with
protocol number, patient number, abbreviated
instructions for use and an institution to return the
part used or empty tube. The full blind treat-
ment code was located in the pharmacology
department of the study site in the form of the
random code list while individual subject code
envelopes were attached to the rear inside cover
of the case report form.
Schedule of efficacy measurements
Following their baseline first antenatal clinic visit
at 13 to 20 weeks gestation (median 16 weeks),
efficacy data were collected at visit 2 (20 to 24 days
post baseline), visit 3 (20 to 24 days post visit 2) and
visit 4 (28 to 24 weeks gestation).
Final data were collected 24 to 48 hours post
delivery. At baseline screen, following eligibility
check list and informed consent, a sterile
Cusco’s speculum was used to sample upper
vaginal secretions. These secretions were exam-
ined using Gram stain for the diagnosis of BV1.
Evidence of clue cells (desquamated epithelial cells
whose margins are obscured by large numbers of
coccobacilli), abnormal vaginal discharge, vaginal
pH and release of amine odor on addition of
10% potassium hydroxide were also recorded. An
endocervical swab and high vaginal swab was
carried out to exclude STD with Neisseria
gonorrhoeae, Chlamydia trachomatis or Trichomonas
vaginalis. If the Gram stain showed evidence of
BV, the patient was randomized to received CVC
or placebo. At visits 2, 3 and 4 Gram stain and
composite criteria were repeated. In the CVC
group, 178 (89.4%), 160 (80.4%) and 153 (76.9%)
attended visits 2, 3 and 4, respectively. This was
similar to those women in the placebo group
whose attendance was 190 (92.7%), 170 (82.9%)
and 162 (79%), respectively.
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Statistical methods
All statistical methods were performed using
an SAS software in a mainframe environment.
Statistical tests were two-sided and p-values of
less than 0.05 were deemed to be statistically
significant. Continuous variables, such as age,
height, past obstetric history, gestational age and
Apgar scores were assumed to have continuous,
symmetric distributions and were analyzed using
two sample t-tests. Categorical variables, such as
race, social history, baseline high vaginal swab,
pregnancy outcome, resolution of BV and propor-
tion of fetomaternal adverse effects were analyzed
using Chi-squared tests. Fisher’s exact test was used
in cases where the expected cell frequency was less
than five. Sample size was calculated on the basis of
the probability of a power of at least 80% (correct
positive) to detect the difference between CVC
and placebo groups of at least 10% in the treat-
ment of BV (cure or improvement) at visit 2 at a
significance level of 5% (false positive).
Measure of efficacy
The primary efficacy measure was the resolution of
BV. At the time of preparation of the protocol, the
1998 Food and Drug Administration (FDA)
Guidance for Studies evaluating the treatment of
bacterial vaginosis had not been published. Only
the FDA recommendations of 1990 were available
and, as now, there was debate as to whether to use
clinical criteria, Gram stain, a combination of the
two or other methods of diagnosing BV. Accord-
ingly, in order to maintain stringency of diagnosis
and to conform to historical diagnostic methods
and available drug agency recommendations at the
time of study design and to allow comparison with
other studies, the resolution of BV was determined
using three distinct definitions of clinical outcome
as follows:
(i) Based on five diagnostic criteria to reflect
stringency of diagnosis (positive Gram stain,
vaginal pH > 4.5, presence of clue cells,
amine odor and characteristic vaginal dis-
charge). Post-treatment, at visit 2, patients
with resolution of these five diagnostic
criteria were considered cured. Patients with
a negative Gram stain with one or more of
the remaining four clinical criteria unre-
solved were considered improved. Patients
with a positive Gram stain (regardless of
composite criteria) were considered failed.
(ii) Based on three diagnostic criteria used to
reflect the historical criteria of Amsel and
co-workers3 (vaginal pH > 4.5, presence of
clue cells and amine odor). Post-treatment, at
visit 2, patients with resolution of all three
diagnostic criteria were considered cured.
Patients with any two criteria resolved were
considered improved and patients with fewer
than two criteria resolved were considered
failed.
(iii) Based on two diagnostic criteria (presence of
clue cells and amine odor), the United States
FDA recommendation that efficacy data
should be analyzed using these criteria were
tested. The FDA based this recommendation
on evidence that the presence of these two
criteria more accurately predicted BV (99%
accuracy) than vaginal fluid6. Post-treatment,
at visit 2, patients with both diagnostic
criteria resolved were considered cured and
patients with either criteria unresolved were
considered failed. The absence of adequate
data to categorize an outcome as cured or
failed were considered non-assessable.
In all the analyses of efficacy for the treatment of
BV, the outcome was assessed at visit 2, though
visit 3 was used to assess recurrence in those
women successfully treated at visit 2. There was
no center-to-center variation in the results of
the evaluation so the group is considered as a
whole. While the analysis is presented as an inten-
tion to treat analysis the observations of safety and
efficacy were identical when those patients who
failed to receive study drug or failed to receive
study drug as per protocol were excluded.
A total of 404 women were studied in an
intention to treat (ITT) analysis comprising 199 in
the CVC group and 205 in the placebo group.
There were no significant differences between the
CVC and placebo groups with respect to age,
weight, height, race, gestational age at baseline,
history of smoking, alcohol or substance abuse
(Table 1). Similarly, there was no significant differ-
ence between the groups with respect to past
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medical history, gravidity, parity or other factors
in the past obstetric history or history of STD. In
total, 224 women, 123 women and 57 women
were recruited from Northwick Park Hospital,
Jessop Hospital, Sheffield and Bolton General
Hospital, respectively. There were no significant
differences between the three centers so the pooled
results of all three centers are presented.
Safety measures
Safety was monitored by the reporting of maternal
and neonatal medical events (ME) including (i)
overall incidence of ME, (ii) overall incidence of
drug-related ME, (iii) overall incidence of ME
leading to dropout, (iv) overall incidence of serious
ME and (v) incidence of maternal and neonatal
death.
RESULTS
Table 2 shows the treatment outcome at visit 2
based on five, three and two diagnostic criteria
using an ITT analysis. With the five diagnostic
(stringent) criteria for cure used in this analysis,
cure rates were 18% for CVC patients and 1.6% for
placebo patients. Improvement rates were 52.6%
for CVC patients and 10.4% for placebo patients
and combined cured and improved rates were
70.8% for CVC patients and 12.0% for placebo
patients. Statistically significant differences
between treatment groups (p < 0.0001) were
observed for the distribution among cured,
improved and failed, as well as for analyses
combining outcomes. Using three diagnostic
criteria, cure rates were considerable higher than
those obtained for the analysis based on five
diagnostic criteria, which follows from the less
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Demographic variable
CVC
n = 199
Placebo
n = 205
Treatment
p-value*
Mean age, yr ± SD
[Range: number reporting]
Mean weight, kg ± SD
[Range: number reporting]
Mean height, m ± SD
[Range: number reporting]
Race:
White
Black
Other
Type of history
Smoking
Yes
No
Cigarettes smoked/day, mean ± SD
Drinking alcohol
Yes
No
Alcoholic drinks/week, mean ± SD
Substance abuse
Yes
No
27.2 ± 5.07
[16–40; n = 198]
66.5 ± 13.42
[40.0–131.5; n = 199]
1.64 ± 0.66
[1.35–1.81; n = 199]
143 (71.9%)
30 (15.1%)
26 (13.1%)
55 (27.6%)
144 (72.4%)
2.5 ± 4.9
42 (21.1%)
157 (78.9%)
0.5 ± 1.9
4 (2.0%)
195 (98.0%)
27.1 ± 5.05
[16–40; n = 205]
64.2 ± 10.97
[42–103; n = 203]
1.63 ± 0.64
[1.46–1.82; n = 205]
136 (66.3%)
35 (17.1%)
34 (16.6%)
67 (32.7%)
138 (67.3%)
3.2 ± 6.3
39 (19.0%)
166 (81.0%)
0.6 ± 1.7
4 (2%)
201 (98%)
0.7009
0.0654
0.1166
0.463
p-value**
0.2695
0.6014
0.9661
CVC, clindamycin vaginal cream. *For age, weight and height, based on two-sample F-test (excluding not reported); for race, based on
Chi-squared test (based on white, black and all other races). Statistics are based on the number of patients reporting data. **Based on
Chi-squared test of yes or no
Table 1 Demographic characteristics and social history of all treated patients at study entry
stringent definition of cure. Cure rates were 44.8%
for CVC patients and 9.3% for placebo patients.
Improvement rates were 32.6% for CVC
patients and 11.5% for placebo patients and
combined cured and improved were 77.3% for
CVC patients and 28.8% for placebo patients.
Statistically significant differences between treat-
ment groups (p < 0.0001) were observed for all
the separate and combined outcomes analyzed.
Using two diagnostic criteria, cure rates were
similar to the combined cured and improved rates
for the analysis based on three diagnostic criteria.
Statistically significant differences in outcome
between treatment groups (p < 0.0001) were
observed. Cure rates were 75.0% for CVC patients
and 18.0% for placebo patients. Recurrence rates at
visit 3 and 4 for those patients cured or improved
at visit 2 (by five criteria) according to criteria-
based diagnosis is shown in Table 3. For CVC
patients, recurrence rates were approximately 6%
at visit 3 and 10% at 28–34 weeks gestation. This
is in contrast to approximately 20% and 25%
for placebo patients, respectively.
Maternal safety outcome
For CVC versus placebo patients, respectively, the
overall incidence of ME (53.8% versus 47.8%),
those ME leading to dropout (0.5% versus 1.5%)
and serious ME (7.5% versus 10.2%) did not differ
significantly. While there was an excess of 20
(10.1%) versus 4 (2.0%) for those women with
greater than or equal to one drug-related ME,
this was due mainly to non-serious conditions
such as vaginal moniliasis (5.5%) and pruritis
(2.0%).
Neonatal safety outcome
For CVC versus placebo patients, respectively, the
overall incidence of ME (12.8% versus 9.5%) and
drug-related ME (0% versus 0%) did not differ
significantly.
There were no maternal deaths. Neonatal
deaths and serious MEs were reported for a similar
percentage of neonates delivered for CVC patients
(deaths 1.5%; serious MEs 5.6%) and placebo
patients (deaths 1.5%; serious MEs 5%). None of
these events was reported to be related to study
medication.
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Treatment outcome
Number of patients (% of group)
Five diagnostic criteria Three diagnostic criteria Two diagnostic criteria
CVC
n = 178
Placebo
n = 190
CVC
n = 178
Placebo
n = 190
CVC
n = 178
Placebo
n = 190
Cured+
Improved++
Failed†
Cured and improved
31 (18)*
90 (52.6)*
50 (29.2)*
121 (70.8)*
3 (1.6)*
19 (10.4)*
161 (88.0)*
22 (12.0)*
77 (44.8)*
56 (32.6)*
39 (22.7)*
133 (73.3)*
17 (9.3)*
21 (11.5)*
145 (79.2)*
38 (28.8)*
129 (75.0)*
N/A
43 (25.0)*
N/A
33 (18.0)*
N/A
150 (82.0)*
N/A
CVC, clindamycin vaginal cream, *p < 0.0001 based on χ2 (placebo versus CVC treatment). +For five criteria, negative Gram stain with
resolution of pH, clue cells, amine odor and discharge; for three criteria, resolution of pH, clue cells and amine odor; for two criteria,
resolution of both clue cells and amine odor. ++For five criteria, negative Gram stain with one or more other criteria unresolved; for three
criteria, two of three resolved (pH, clue cells, amine odor). †For five criteria, positive Gram stain; for three criteria, one of three resolved
(pH, clue cells, amine odor); for two criteria, clue cells or amine odor unresolved
Table 2 Intention to treat analysis of the outcome at visit 2, based on five, three and two diagnostic criteria
Diagnostic
basis
Visit 3 Visit 4
CVC Placebo CVC Placebo
5-criteria
3-criteria
2-criteria
6.3%
5.4%
7.1%
15%
20%
25%
10.3%
8.4%
11.2%
23.8%
25%
25%
CVC, clindamycin vaginal cream
Table 3 Intention to treat analysis of recurrence rate
in CVC-treated patients at visits 3 and 4 for those cured
or improved at visit 2
DISCUSSION
This study has shown that by whatever criteria of
efficacy, a 3-day course of CVC used in the second
trimester of pregnancy is an effective way to treat
abnormal genital tract flora manifest by bacterial
vaginosis on Gram stain of vaginal secretions. The
effect this treatment has on the outcome of
pregnancy has been the subject of a separate
report7. Clindamycin phosphate 2% vaginal cream
has been shown to be effective in the treatment of
non-pregnant women with BV8,9. A 7-day regime
is approved for this indication in many countries.
Clindamycin 2% cream is associated with few
side-effects and only a small fraction (approxi-
mately 4%) is absorbed systemically10. This study is
the largest study to examine the efficacy and safety
of CVC in pregnancy and the only study to
examine a 3-day course in pregnancy. In pregnant
women, a 7-day course is effective11. In non-
pregnant women a 3-day course was as effective as
a 7-day course12 and significantly better than
placebo13. A 3-day course is likely to be much
more acceptable than a 7-day course and therefore
more likely to increase patient compliance.
Historically, the diagnosis of BV has been based on
three out of four clinical criteria according to the
original study of Amsel and co-workers3. The use
of composite criteria is clumsy, unpleasant and
irreproducible and likely to be replaced by Gram
stain, which has excellent specificity and sensitivity
when measured against composite criteria2. In
view of this, three diagnostic methods based on
five, three and two criteria corresponding to a
very stringent diagnosis including Gram stain,
the Amsel classification3 and the US FDA
recommendation6, respectively, were chosen to
reflect the range of diagnostic criteria used at the
time of study design. Using the current American
FDA guidelines, the evaluation of the studies for
the treatment of BV would correspond with the
five criteria diagnostic method, a combination of
Gram stain and all four clinical criteria. Some still
feel that the Amsel clinical criteria should be the
gold standard and at the time the study was
conducted only the 1990 FDA recommendations
were available and these suggested using two
criteria. With all these diagnostic criteria, clinda-
mycin vaginal cream 2% administered as a 5 g dose
once nightly for three consecutive nights was
found to be statistically significantly superior to
placebo and effective in the treatment of BV
during the second trimester of pregnancy. Of those
patients in the five, three and two criteria diagnos-
tic groups, 18%, 44.8% and 75.0% in the treatment
group and 1.6%, 9.3% and 18.0% in the placebo
group, respectively, were cured (p < 0.0001). In
the five and three criteria diagnostic groups, 70.8%
and 77.3% in the treatment group and 12.0% and
28.8% in the placebo group, respectively, showed
either cure or improvement (p < 0.0001). With
only two diagnostic criteria there was no accept-
able definition for improved so this last group could
not be included in a cured and improved category.
A cure rate of 44.8% based on three diagnostic
criteria compared favorably with the 7-day
unpublished study11 where the corresponding cure
rate was 50.8% using a less stringent definition of
cure (resolution of any three out of four criteria).
Relative to the 7-day unpublished study11, a lower
number of CVC patients in our study reported any
medical events and the proportion of CVC
patients in our study with events considered to be
drug-related was about half of the earlier study.
The treatment appears to be well tolerated in this
patient population and was not considered to have
caused any adverse neonatal or serious maternal
events. Recurrence rates were low at approxi-
mately 6% at visit 3 and 10% at 28 to 34 weeks
gestation.
Bacterial vaginosis is thought to account for up
to one-third of vulvovaginal infectious morbidity
and is associated with adverse sequelae in both
obstetrics and gynaecology14. The symptoms
relating to BV are said to account for 10 million
clinic visits annually in the USA15. Prevalence rates
vary according to population studied but in an
unselected, antenatal population in a district
general hospital in the UK, 15% of women at the
first antenatal visit were found to have this
condition16. Although up to half of these women
with BV may be asymptomatic, women who are
symptomatic may experience a distressing, mal-
odorous, offensive vaginal discharge due to volatile
amines released at high pH from their stable salt
form at low pH. BV in pregnancy is associated with
postpartum endometritis17 and chorioamnionitis18.
A large number of studies have shown an associ-
ation between BV and preterm prelabor rupture of
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the membranes and preterm delivery and late
miscarriage and these have recently been
reviewed19. Kurki and co-workers found a 2.6-fold
increased risk of preterm labor and a 6.9-fold
increased risk of preterm delivery with BV in early
pregnancy20. In South-East Asia, the risk of
preterm delivery was almost double among those
women diagnosed as having BV in early pregnancy
(21%) compared to those who developed the con-
dition in late pregnancy (11%)21. Using multiple
logistic regression analysis, BV was found to be
associated with a five-fold increased risk of preterm
delivery when BV was detected before 16 weeks
gestation independent of recognized risk factors
such as previous preterm birth, black race and
smoking16. Hay and co-workers also found a five-
fold increased risk of late miscarriage in women
with BV in early pregnancy16 and women with
recurrent second trimester miscarriages were far
more likely to be colonized by BV than women
with a history of recurrent first trimester mis-
carriages22. A number of studies have examined
whether the detection and treatment of BV in
pregnancy would reduce the morbidity and
mortality associated with preterm delivery.
Unfortunately these studies have varied in the
choice of antibiotic, dose regime, route of admin-
istration, level of patient risk, gestational age at
administration and success or failure, so no
consensus has yet been reached about whether or
not antibiotics are effective23. The effect of this
treatment in our study on the outcome of
pregnancy was the subject of a separate report7
which showed a 60% statistically significant
reduction in the incidence of preterm birth from
10% with placebo to 4% with CVC. There is logic
in using intravaginal antibiotics for the treatment
of BV in pregnancy since a large load of anti-
biotics is administered directly to where there is
the heaviest colonization. There is also less likely
to be unacceptable systemic side-effects.
Different bacterial species are distributed in
different ways according to the different grades
of Gram stain. Mycoplasma hominis, Gardnerella
vaginalis and some anaerobes are only fully
expressed in grade 3 Gram stain BV24. It may
be that this represents a subgroup of women with
BV in pregnancy that are most likely to benefit
from CVC25.
BV in pregnancy should be treated either to
give symptomatic relief or following opportunistic
screening of high risk women found to have
BV to reduce the risks of adverse obstetric
sequelae5. This study has shown that a 3-day
course of CVC 2% is well tolerated and an effective
way of treating BV in the second trimester of
pregnancy.
Three other studies used CVC prophy-
lactically23,26,27 for the prevention of preterm birth
without success but these have been criticized28.
In one study23 100% of women were treated after
20 weeks gestation and in the other26 60% of
women were treated after 20 weeks. In the study
by Vermeulen27 risk was based on previous pre-
term birth and the mean gestation at random-
ization was 20 weeks. This is in contrast to our
published data7 where all women were treated
before 20 weeks gestation and 60% were treated
before 16 weeks. We have also pointed out29 that
in the Vermeulen study, none of the seven women
who delivered preterm had BV. This suggests
other non-infectious pathology and a self-fulfilling
prophesy that antibiotics would be unhelpful. In
a subsequent report, Vermeulen and co-workers
claimed that CVC, rather than preventing preterm
birth, caused neonatal infectious morbidity30. We
have pointed out the reason for this, that
Vermeulen and colleagues are not eradicating
abnormal colonization in early pregnancy, rather,
they are decimating normal flora late in
pregnancy31. We also pointed out that three of the
references quoted in that paper about the use of
CVC in pregnancy were erroneous. In all three
studies pregnancy was a contraindication to study
entry, in one of the studies recruitment was from a
STI clinic and in another study 14% of the women
had had a hysterectomy. We have received no
response from the corresponding author.
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